Since MD3–22 received high intensity post-remission therapy we focused on signaling associated with sample MD2–22 obtained from a patient who received high dose cytarabine similar to what is recommended for “low risk” cytogenetic leukemia. The gene discussed is LY96; the disease is leukemia.